Evidence map›Paper›PMID 41327075›Full record

ArticleBMC medical research methodology2025

Dealing with differential misclassification of an outcome or a covariate in association studies with an internally validated sample selected not at random.

Júlia Lacombe Ossó, Benjamin Glemain, Céline Dorival, Hélène Blanché, Cédric Lemogne, Jean-François Deleuze, Olivier Robineau, Mathilde Touvier, Gianluca Severi, Marie Zins and 3 more

Abstract read
In one paragraph

Article in BMC medical research methodology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Júlia Lacombe OssóSorbonne Université, INSERM, Institut Pierre Louis d'Épidémiologie Et de Santé Publique, 27 Rue Chaligny, 75571, Cedex 12, Paris, France.
Benjamin GlemainSorbonne Université, INSERM, Institut Pierre Louis d'Épidémiologie Et de Santé Publique, 27 Rue Chaligny, 75571, Cedex 12, Paris, France.
Céline DorivalSorbonne Université, INSERM, Institut Pierre Louis d'Épidémiologie Et de Santé Publique, 27 Rue Chaligny, 75571, Cedex 12, Paris, France.
Hélène BlanchéFondation Jean Dausset-CEPH (Centre d'Etude du Polymorphisme Humain), CEPH-Biobank, Paris, France.
Cédric LemogneCenter for Research in Epidemiology and StatisticS (CRESS), Université Paris Cité and Université Sorbonne Paris Nord, Inserm, INRAE, Paris, France.
Jean-François DeleuzeFondation Jean Dausset-CEPH (Centre d'Etude du Polymorphisme Humain), CEPH-Biobank, Paris, France.
Olivier RobineauSorbonne Université, INSERM, Institut Pierre Louis d'Épidémiologie Et de Santé Publique, 27 Rue Chaligny, 75571, Cedex 12, Paris, France.
Mathilde TouvierCnam, Nutritional Epidemiology Research Team (EREN), Center for Research in Epidemiology and StatisticS (CRESS), Sorbonne Paris Nord University, Inserm U1153, Inrae U1125, Bobigny, France.
Gianluca SeveriCESP UMR1018, Université Paris-Saclay, UVSQ, Inserm, Gustave Roussy, Villejuif, France.
Marie ZinsParis University, Paris, France.
SAPRIS-SERO study group
Xavier de LamballerieUnité Des Virus Émergents, UVE, Aix Marseille Univ, IHU Méditerranée Infection, IRD 190, INSERM 1207, Marseille, France.
Fabrice CarratSorbonne Université, INSERM, Institut Pierre Louis d'Épidémiologie Et de Santé Publique, 27 Rue Chaligny, 75571, Cedex 12, Paris, France. fabrice.carrat@iplesp.upmc.fr.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTo present an analytical framework for correcting misclassification when an imperfect test is used as an indicator of a disease in association studies, taking into account that part of the sample has joint test and disease data.

methodsWe explored two scenarios, depending on whether the disease is a covariate or the outcome. The analysis sample includes an internal validation sample where the disease status is known in addition to the test. Joint likelihood models taking into account classification errors and the possible selection of the validation sample not at random were used. Simulations were performed to evaluate the methods. We illustrated our framework using data from a multi-cohort COVID-19 serological study conducted in France between 2020 and 2021, with serology as the imperfect test and SARS-CoV-2 infection as the disease. The dataset included concomitant measurements of the serological test and the SARS-CoV-2 infection status determined using additional virologic methods (PCR, neutralization assay) in 7% participants. We estimated 1) the association between incident persistent symptoms defined as a symptom lasting at least 8 weeks (outcome) and infection (covariate) and 2) the association between infection (outcome) and several covariates. For comparison, we also estimated 'naïve' models using serology without correction or using the internal validation sample only, as well as models under different assumptions about the missingness pattern of the SARS-CoV-2 infection status.

resultsSimulations confirmed the methods' abilities to correct for misclassification and not at random selection of the validation sample. In the application, the estimated sensitivities and specificities of the serological test with respect to SARS-CoV-2 infection were 86.2%-87.7% and 95.8%-97.5%, respectively. Considering SARS-CoV-2 infection as a covariate, the corrected analysis identified a significant association between infection and persistent symptoms. Considering SARS-CoV-2 infection as the outcome, the corrected analysis identified an association between infection and age, gender and active smoking, but did not retrieve an association with living with at least one child at home and previous smoking, which were identified in the naïve analysis.

conclusionThis methodological framework can be applied in association studies when an imperfect test is used as an indicator of a disease and the disease status has been validated in a subset of the sample. We extended previous works to deal with not at random selection of this validated sample.

Indexed as

COVID-19COVID-19 Serological TestingAdultCohort StudiesComputer SimulationFemaleFranceHumansLikelihood FunctionsMaleMiddle AgedSARS-CoV-2Differential MisclassificationEpidemiologic BiasesImperfect TestLikelihoodMARMCARMNARSampling biasSARS-CoV-2Serology

Identifiers

PMID41327075
PMCPMC12667108

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.